Loading…
Reported covered position: Legislative Assistant for Rep. Carolyn Cheeks Kilpatrick
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
GILEAD SCIENCES INC via GILEAD SCIENCES, INC.
2026 · third_quarter · 3A
Advocate for provisions modifying the Inflation Reduction Act and other drug pricing proposals. HCV testing, screening and linkage to care programs. Medicaid and Medicare coverage, access and reimbursement issues for Hepatitis C, HIV, oncology products, and COVID-19 therapies and prevention including Medicare Part B proposals, and Medicare Part D reform and benefit redesign. CMS rules, including those related to payments in Medicare, Medicaid drug rebates, and proposed CMMI demonstrations.
Funding for policies relating to domestic and international HIV, Hepatitis C, oncology, and public health activities via appropriations. Advocacy regarding drug pricing proposals, including provisions modifying the Inflation Reduction Act and government purchasing proposals.
Source: Senate LDA
Advocate on domestic and global drug pricing proposals, international trade and protection of intellectual property; global supply chain issues, including the Medical Supply Chain Resiliency Act and tariffs; compulsory licensing and other IP issues in multiple countries.
Advocate on drug pricing proposals. Proposals to expand access to HIV treatment and prevention therapies including: Ryan White Care Act reauthorization; PEPFAR; HIV/AIDS access to care, research, testing and treatment. Hepatitis C screening and linkage to care programs; coverage and reimbursement policy for Hepatitis C, HIV and oncology portfolio. Issues related to triple negative breast cancer (TNBC) and early detection and screenings for breast cancer. Advocate in favor of 340B program reforms and changes. Issues related to developing treatments and therapies, including: manufacturing, clinical trials, reimbursement and coverage.
Filing targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), Office of Management & Budget (OMB), Patent & Trademark Office (PTO), SENATE, State, Dept of (DOS), Treasury, Dept of, U.S. Trade Representative (USTR), White House Office
GILEAD SCIENCES INC via GILEAD SCIENCES, INC.
2026 · third_quarter · Q3
Funding for policies relating to domestic and international HIV, Hepatitis C, oncology, and public health activities via appropriations. Advocacy regarding drug pricing proposals, including provisions modifying the Inflation Reduction Act and government purchasing proposals.
Advocate on domestic and global drug pricing proposals, international trade and protection of intellectual property; global supply chain issues, including the Medical Supply Chain Resiliency Act and tariffs; compulsory licensing and other IP issues in multiple countries.
Advocate on drug pricing proposals. Proposals to expand access to HIV treatment and prevention therapies including: Ryan White Care Act reauthorization; PEPFAR; HIV/AIDS access to care, research, testing and treatment. Hepatitis C screening and linkage to care programs; coverage and reimbursement policy for Hepatitis C, HIV and oncology portfolio. Issues related to triple negative breast cancer (TNBC) and early detection and screenings for breast cancer. Advocate in favor of 340B program reforms and changes. Issues related to developing treatments and therapies, including: manufacturing, clinical trials, reimbursement and coverage.
Advocate for provisions modifying the Inflation Reduction Act and other drug pricing proposals. HCV testing, screening and linkage to care programs. Medicaid and Medicare coverage, access and reimbursement issues for Hepatitis C, HIV, oncology products, and COVID-19 therapies and prevention including Medicare Part B proposals, and Medicare Part D reform and benefit redesign. CMS rules, including those related to payments in Medicare, Medicaid drug rebates, and proposed CMMI demonstrations.
Filing targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), Office of Management & Budget (OMB), Patent & Trademark Office (PTO), SENATE, State, Dept of (DOS), Treasury, Dept of, U.S. Trade Representative (USTR), White House Office
GILEAD SCIENCES INC via GILEAD SCIENCES, INC.
2026 · second_quarter · Q2
Advocate on drug pricing proposals. Proposals to expand access to HIV treatment and prevention therapies including: Ryan White Care Act reauthorization; PEPFAR; HIV/AIDS access to care, research, testing and treatment. Hepatitis C screening and linkage to care programs; coverage and reimbursement policy for Hepatitis C, HIV and oncology portfolio. Issues related to triple negative breast cancer (TNBC) and early detection and screenings for breast cancer. Advocate in favor of 340B program reforms and changes. Issues related to developing treatments and therapies, including: manufacturing, clinical trials, reimbursement and coverage.
Advocate on domestic and global drug pricing proposals, international trade and protection of intellectual property; global supply chain issues, including the Medical Supply Chain Resiliency Act and tariffs; compulsory licensing and other IP issues in multiple countries.
Funding for policies relating to domestic and international HIV, Hepatitis C, oncology, and public health activities via appropriations. Advocacy regarding drug pricing proposals, including provisions modifying the Inflation Reduction Act and government purchasing proposals.
Advocate for provisions modifying the Inflation Reduction Act and other drug pricing proposals. HCV testing, screening and linkage to care programs. Medicaid and Medicare coverage, access and reimbursement issues for Hepatitis C, HIV, oncology products, and COVID-19 therapies and prevention including Medicare Part B proposals, and Medicare Part D reform and benefit redesign. CMS rules, including those related to payments in Medicare, Medicaid drug rebates, and proposed CMMI demonstrations.
Filing targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), Office of Management & Budget (OMB), Patent & Trademark Office (PTO), SENATE, State, Dept of (DOS), Treasury, Dept of, U.S. Trade Representative (USTR), White House Office
GILEAD SCIENCES INC via GILEAD SCIENCES, INC.
2026 · first_quarter · Q1
Advocate on domestic and global drug pricing proposals, international trade and protection of intellectual property; global supply chain issues, including the Medical Supply Chain Resiliency Act and tariffs; compulsory licensing and other IP issues in multiple countries.
Advocate on drug pricing proposals. Proposals to expand access to HIV treatment and prevention therapies including: Ryan White Care Act reauthorization; PEPFAR; HIV/AIDS access to care, research, testing and treatment. Hepatitis C screening and linkage to care programs; coverage and reimbursement policy for Hepatitis C, HIV and oncology portfolio. Issues related to triple negative breast cancer (TNBC) and early detection and screenings for breast cancer. Advocate in favor of 340B program reforms and changes. Issues related to developing treatments and therapies, including: manufacturing, clinical trials, reimbursement and coverage.
Advocate for provisions modifying the Inflation Reduction Act and other drug pricing proposals. HCV testing, screening and linkage to care programs. Medicaid and Medicare coverage, access and reimbursement issues for Hepatitis C, HIV, oncology products, and COVID-19 therapies and prevention including Medicare Part B proposals, and Medicare Part D reform and benefit redesign. CMS rules, including those related to payments in Medicare, Medicaid drug rebates, and proposed CMMI demonstrations.
Funding for policies relating to domestic and international HIV, Hepatitis C, oncology, and public health activities via appropriations. Advocacy regarding drug pricing proposals, including provisions modifying the Inflation Reduction Act and government purchasing proposals.
Filing targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), Office of Management & Budget (OMB), Patent & Trademark Office (PTO), SENATE, State, Dept of (DOS), Treasury, Dept of, U.S. Trade Representative (USTR), White House Office
GILEAD SCIENCES INC via GILEAD SCIENCES, INC.
2025 · fourth_quarter · Q4
Advocate on drug pricing proposals, international trade and protection of intellectual property; global supply chain issues, including the Medical Supply Chain Resiliency Act and tariffs; compulsory licensing and other IP issues in multiple countries.
Advocate on drug pricing proposals and proposals to expand access to HIV treatment and prevention therapies including: Ryan White Care Act reauthorization; PEPFAR; HIV/AIDS access to care, research, testing and treatment. Hepatitis C screening and linkage to care programs; coverage and reimbursement policy for Hepatitis C, HIV and oncology portfolio. Issues related to triple negative breast cancer (TNBC) and early detection and screenings for breast cancer. Advocate in favor of 340B program reforms and changes. Highlight Gilead's efforts to ensure diversity in clinical trials. Issues related to developing treatments and therapies, including: manufacturing, clinical trials, reimbursement and coverage.
Advocate for provisions modifying the Inflation Reduction Act and other drug pricing proposals. HCV testing, screening and linkage to care programs. Medicaid and Medicare coverage, access and reimbursement issues for Hepatitis C, HIV, oncology products, and COVID-19 therapies and prevention including Medicare Part B proposals, and Medicare Part D reform and benefit redesign. CMS rules related to hospital inpatient payments, Medicaid Drug Rebate Program, and Value-Based Purchasing arrangements including changes to best price.
Funding for policies relating to domestic and international HIV, Hepatitis C, oncology, and public health activities via appropriations. Advocacy regarding drug pricing proposals, including provisions modifying the Inflation Reduction Act and government purchasing proposals.
Filing targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), Office of Management & Budget (OMB), Patent & Trademark Office (PTO), SENATE, State, Dept of (DOS), Treasury, Dept of, U.S. Trade Representative (USTR), White House Office
GILEAD SCIENCES INC via GILEAD SCIENCES, INC.
2025 · third_quarter · Q3
Advocate on drug pricing proposals, international trade and protection of intellectual property; global supply chain issues, including the Medical Supply Chain Resiliency Act and tariffs; compulsory licensing and other IP issues in multiple countries.
Advocate on drug pricing proposals and proposals to expand access to HIV treatment and prevention therapies including: Ryan White Care Act reauthorization; PEPFAR; HIV/AIDS access to care, research, testing and treatment. Hepatitis C screening and linkage to care programs; coverage and reimbursement policy for Hepatitis C, HIV and oncology portfolio. Issues related to triple negative breast cancer (TNBC) and early detection and screenings for breast cancer. Advocate in favor of 340B program reforms and changes. Highlight Gilead's efforts to ensure diversity in clinical trials. Issues related to developing treatments and therapies, including: manufacturing, clinical trials, reimbursement and coverage.
GILEAD SCIENCES INC via GILEAD SCIENCES, INC.
2025 · second_quarter · Q2
Advocate on drug pricing proposals and proposals to expand access to HIV treatment and prevention therapies including: Ryan White Care Act reauthorization; PEPFAR; HIV/AIDS access to care, research, testing and treatment. Hepatitis C screening and linkage to care programs; coverage and reimbursement policy for Hepatitis C, HIV and oncology portfolio. Issues related to triple negative breast cancer (TNBC) and early detection and screenings for breast cancer. Advocate in favor of 340B program reforms and changes. Highlight Gilead's efforts to ensure diversity in clinical trials. Issues related to developing treatments and therapies, including: manufacturing, clinical trials, reimbursement and coverage.
Advocate on drug pricing proposals, international trade and protection of intellectual property; global supply chain issues, including the Medical Supply Chain Resiliency Act and tariffs; compulsory licensing and other IP issues in multiple countries.
GILEAD SCIENCES INC via GILEAD SCIENCES, INC.
2025 · first_quarter · Q1
International trade and protection of intellectual property; TRIPS Waiver; global supply chain issues, including the Medical Supply Chain Resiliency Act; compulsory licensing and other IP issues in multiple countries.
Advocate on drug pricing proposals and proposals to expand access to HIV treatment and prevention therapies including: Ryan White Care Act reauthorization; PEPFAR reauthorization; HIV/AIDS access to care, research, testing and treatment. Hepatitis C screening and linkage to care programs; coverage and reimbursement policy for Hepatitis C, HIV and oncology portfolio. Issues related to triple negative breast cancer (TNBC) and early detection and screenings for breast cancer. Advocate in favor of 340B program reforms and changes to Notice of Benefit and Payment Parameters (NBPP). Highlight Gilead's efforts to ensure diversity in clinical trials. Issues related to developing treatments and therapies, including: manufacturing, clinical trials, reimbursement and coverage.
GILEAD SCIENCES INC via GILEAD SCIENCES, INC.
2024 · fourth_quarter · Q4
International trade and protection of intellectual property; TRIPS Waiver; global supply chain issues, including the Medical Supply Chain Resiliency Act; compulsory licensing and other IP issues in multiple countries.
Advocate on drug pricing proposals and proposals to expand access to HIV treatment and prevention therapies including: Ryan White Care Act reauthorization; PEPFAR reauthorization; HIV/AIDS access to care, research, testing and treatment. Hepatitis C screening and linkage to care programs; coverage and reimbursement policy for Hepatitis C, HIV and oncology portfolio. Issues related to triple negative breast cancer (TNBC) and early detection and screenings for breast cancer. Advocate in favor of 340B program reforms and changes to Notice of Benefit and Payment Parameters (NBPP). Highlight Gilead's efforts to ensure diversity in clinical trials. Issues related to developing treatments and therapies, including: manufacturing, clinical trials, reimbursement and coverage.
GILEAD SCIENCES INC via GILEAD SCIENCES, INC.
2024 · third_quarter · Q3
Advocate against expansion of drug pricing proposals, including provisions modifying the Inflation Reduction Act. HCV testing, screening and linkage to care programs. Medicaid and Medicare coverage, access and reimbursement issues for Hepatitis C, HIV, oncology products, and COVID-19 therapies and prevention including Medicare Part B proposals, and Medicare Part D reform and benefit redesign. CMS rules related to Notice of Benefit and Payment Parameters (NBPP), hospital inpatient payments, Medicaid Drug Rebate Program, and Value-Based Purchasing arrangements including changes to best price.
Advocate on drug pricing proposals and proposals to expand access to HIV treatment and prevention therapies including: Ryan White Care Act reauthorization; PEPFAR reauthorization; HIV/AIDS access to care, research, testing and treatment. Hepatitis C screening and linkage to care programs; coverage and reimbursement policy for Hepatitis C, HIV and oncology portfolio. Issues related to triple negative breast cancer (TNBC) and early detection and screenings for breast cancer. Engage on pharmaceutical policy as it relates to payments under the 340B program. Highlight Gilead's efforts to ensure diversity in clinical trials. Issues related to developing treatments and therapies, including: manufacturing, clinical trials, reimbursement and coverage.
GILEAD SCIENCES INC via GILEAD SCIENCES, INC.
2024 · second_quarter · Q2
Advocate against expansion of drug pricing proposals, including provisions modifying the Inflation Reduction Act. HCV testing, screening and linkage to care programs. Medicaid and Medicare coverage, access and reimbursement issues for Hepatitis C, HIV, oncology products, and COVID-19 therapies and prevention including Medicare Part B proposals, and Medicare Part D reform and benefit redesign. CMS rules related to Notice of Benefit and Payment Parameters (NBPP), hospital inpatient payments, Medicaid Drug Rebate Program, and Value-Based Purchasing arrangements including changes to best price.
Advocate on drug pricing proposals and proposals to expand access to HIV treatment and prevention therapies including: Ryan White Care Act reauthorization; PEPFAR reauthorization; HIV/AIDS access to care, research, testing and treatment. Hepatitis C screening and linkage to care programs; coverage and reimbursement policy for Hepatitis C, HIV and oncology portfolio. Issues related to triple negative breast cancer (TNBC) and early detection and screenings for breast cancer. Engage on pharmaceutical policy as it relates to payments under the 340B program. Highlight Gilead's efforts to ensure diversity in clinical trials. Issues related to developing treatments and therapies, including: manufacturing, clinical trials, reimbursement and coverage.
GILEAD SCIENCES INC via GILEAD SCIENCES, INC.
2024 · first_quarter · Q1
Advocate against expansion of drug pricing proposals, including provisions modifying the Inflation Reduction Act. HCV testing, screening and linkage to care programs. Medicaid and Medicare coverage, access and reimbursement issues for Hepatitis C, HIV, oncology products, and COVID-19 therapies and prevention including Medicare Part B proposals, and Medicare Part D reform and benefit redesign. CMS rules related to Notice of Benefit and Payment Parameters (NBPP), hospital inpatient payments, Medicaid Drug Rebate Program, and Value-Based Purchasing arrangements including changes to best price.
Advocate on drug pricing proposals and proposals to expand access to HIV treatment and prevention therapies including: Ryan White Care Act reauthorization; PEPFAR reauthorization; HIV/AIDS access to care, research, testing and treatment. Hepatitis C screening and linkage to care programs; coverage and reimbursement policy for Hepatitis C, HIV and oncology portfolio. Issues related to triple negative breast cancer (TNBC) and early detection and screenings for breast cancer. Engage on pharmaceutical policy as it relates to payments under the 340B program. Highlight Gilead's efforts to ensure diversity in clinical trials. Issues related to developing treatments for COVID-19 and other viral pathogens, including: manufacturing, clinical trials, reimbursement and coverage.
GILEAD SCIENCES INC via GILEAD SCIENCES, INC.
2023 · fourth_quarter · Q4
Advocate against expansion of drug pricing proposals, including provisions modifying the Inflation Reduction Act. HCV testing, screening and linkage to care programs. Medicaid and Medicare coverage, access and reimbursement issues for Hepatitis C, HIV, oncology products, and COVID-19 therapies including Medicare Part B proposals, and Medicare Part D reform and benefit redesign. CMS rules related to Notice of Benefit and Payment Parameters (NBPP), hospital inpatient payments, and Value-Based Purchasing arrangements including changes to best price.
Advocate on drug pricing proposals and proposals to expand access to HIV treatment and prevention therapies including: Ryan White Care Act reauthorization; PEPFAR reauthorization; HIV/AIDS access to care, research, testing and treatment. Hepatitis C screening and linkage to care programs; coverage and reimbursement policy for Hepatitis C, HIV and oncology portfolio. Issues related to triple negative breast cancer (TNBC) and early detection and screenings for breast cancer. Engage on pharmaceutical policy as it relates to payments under the 340B program. Highlight Gilead's efforts to ensure diversity in clinical trials. Issues related to developing treatments for COVID-19 (2019 Novel Coronavirus), including: manufacturing, clinical trials, reimbursement and coverage of Veklury (remdesivir).
GILEAD SCIENCES INC via GILEAD SCIENCES, INC.
2023 · third_quarter · Q3
Funding for Hepatitis C, HIV, oncology, and public health activities via appropriations. Advocate against expansion of drug pricing proposals, including provisions modifying the Inflation Reduction Act.
Advocate against expansion of drug pricing proposals, including provisions modifying the Inflation Reduction Act. HCV testing, screening and linkage to care programs. Medicaid and Medicare coverage, access and reimbursement issues for Hepatitis C, HIV, oncology products, and COVID-19 therapies including Medicare Part B proposals, and Medicare Part D reform and benefit redesign. CMS rules related to Notice of Benefit and Payment Parameters (NBPP), hospital inpatient payments, and Value-Based Purchasing arrangements including changes to best price.
Advocate for provisions modifying the Inflation Reduction Act and other drug pricing proposals. HCV testing, screening and linkage to care programs. Medicaid and Medicare coverage, access and reimbursement issues for Hepatitis C, HIV, oncology products, and COVID-19 therapies and prevention including Medicare Part B proposals, and Medicare Part D reform and benefit redesign. CMS rules related to hospital inpatient payments, Medicaid Drug Rebate Program, and Value-Based Purchasing arrangements including changes to best price.
Funding for policies relating to domestic and international HIV, Hepatitis C, oncology, and public health activities via appropriations. Advocacy regarding drug pricing proposals, including provisions modifying the Inflation Reduction Act and government purchasing proposals.
Filing targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), Office of Management & Budget (OMB), Patent & Trademark Office (PTO), SENATE, State, Dept of (DOS), Treasury, Dept of, U.S. Trade Representative (USTR), White House Office
Advocate for provisions modifying the Inflation Reduction Act and other drug pricing proposals. HCV testing, screening and linkage to care programs. Medicaid and Medicare coverage, access and reimbursement issues for Hepatitis C, HIV, oncology products, and COVID-19 therapies and prevention including Medicare Part B proposals, and Medicare Part D reform and benefit redesign. CMS rules related to hospital inpatient payments, Medicaid Drug Rebate Program, and Value-Based Purchasing arrangements including changes to best price.
Funding for policies relating to domestic and international HIV, Hepatitis C, oncology, and public health activities via appropriations. Advocacy regarding drug pricing proposals, including provisions modifying the Inflation Reduction Act and government purchasing proposals.
Filing targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), Office of Management & Budget (OMB), Patent & Trademark Office (PTO), SENATE, State, Dept of (DOS), Treasury, Dept of, U.S. Trade Representative (USTR), White House Office
Advocate for provisions modifying the Inflation Reduction Act. HCV testing, screening and linkage to care programs. Medicaid and Medicare coverage, access and reimbursement issues for Hepatitis C, HIV, oncology products, and COVID-19 therapies and prevention including Medicare Part B proposals, and Medicare Part D reform and benefit redesign. CMS rules related to hospital inpatient payments, Medicaid Drug Rebate Program, and Value-Based Purchasing arrangements including changes to best price.
Funding for policies relating to domestic and international HIV, Hepatitis C, oncology, and public health activities via appropriations. Advocacy regarding drug pricing proposals, including provisions modifying the Inflation Reduction Act and government purchasing proposals.
Filing targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), Office of Science & Technology Policy (OSTP), Office of the Vice President of the United States, Patent & Trademark Office (PTO), SENATE, State, Dept of (DOS), Treasury, Dept of, U.S. Trade Representative (USTR), White House Office
Funding for and policies relating to Hepatitis C, HIV, oncology, and public health activities via appropriations. Advocacy regarding drug pricing proposals, including provisions modifying the Inflation Reduction Act and government purchasing proposals.
Advocate against expansion of drug pricing proposals, including provisions modifying the Inflation Reduction Act. HCV testing, screening and linkage to care programs. Medicaid and Medicare coverage, access and reimbursement issues for Hepatitis C, HIV, oncology products, and COVID-19 therapies and prevention including Medicare Part B proposals, and Medicare Part D reform and benefit redesign. CMS rules related to hospital inpatient payments, Medicaid Drug Rebate Program, and Value-Based Purchasing arrangements including changes to best price.
Filing targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), Office of Management & Budget (OMB), Office of Science & Technology Policy (OSTP), Office of the Vice President of the United States, Patent & Trademark Office (PTO), SENATE, State, Dept of (DOS), Treasury, Dept of, U.S. Trade Representative (USTR), White House Office
Funding for and policies relating to Hepatitis C, HIV, oncology, and public health activities via appropriations. Advocacy regarding drug pricing proposals, including provisions modifying the Inflation Reduction Act and government purchasing proposals.
Filing targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), Office of Management & Budget (OMB), Office of the Vice President of the United States, Patent & Trademark Office (PTO), SENATE, State, Dept of (DOS), Treasury, Dept of, U.S. Trade Representative (USTR), White House Office
Funding for and policies relating to Hepatitis C, HIV, oncology, and public health activities via appropriations. Advocacy regarding drug pricing proposals, including provisions modifying the Inflation Reduction Act and government purchasing proposals.
Filing targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), Natl Security Council (NSC), Office of Management & Budget (OMB), Office of the Vice President of the United States, Patent & Trademark Office (PTO), SENATE, State, Dept of (DOS), Treasury, Dept of, U.S. Trade Representative (USTR), White House Office
Funding for and policies relating to Hepatitis C, HIV, oncology, and public health activities via appropriations. Advocacy regarding drug pricing proposals, including provisions modifying the Inflation Reduction Act and government purchasing proposals.
Filing targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), Natl Security Council (NSC), Office of Management & Budget (OMB), Office of the Vice President of the United States, Patent & Trademark Office (PTO), SENATE, State, Dept of (DOS), Treasury, Dept of, U.S. Trade Representative (USTR), White House Office
Funding for Hepatitis C, HIV, oncology, and public health activities via appropriations. Advocate against expansion of drug pricing proposals, including provisions modifying the Inflation Reduction Act.
Filing targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), Natl Security Council (NSC), Office of Management & Budget (OMB), Office of the Vice President of the United States, Patent & Trademark Office (PTO), SENATE, State, Dept of (DOS), Treasury, Dept of, U.S. Trade Representative (USTR), White House Office
Advocate on drug pricing proposals and proposals to expand access to HIV treatment and prevention therapies including: Ryan White Care Act reauthorization; PEPFAR reauthorization; HIV/AIDS access to care, research, testing and treatment. Hepatitis C screening and linkage to care programs; coverage and reimbursement policy for Hepatitis C, HIV and oncology portfolio. Issues related to triple negative breast cancer (TNBC) and early detection and screenings for breast cancer. Engage on pharmaceutical policy as it relates to payments under the 340B program. Highlight Gilead's efforts to ensure diversity in clinical trials. Issues related to developing treatments for COVID-19 (2019 Novel Coronavirus), including: manufacturing, clinical trials, reimbursement and coverage of Veklury (remdesivir).
Filing targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), Natl Security Council (NSC), Office of Management & Budget (OMB), Office of the Vice President of the United States, Patent & Trademark Office (PTO), SENATE, State, Dept of (DOS), Treasury, Dept of, U.S. Trade Representative (USTR), White House Office